SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-065132
Filing Date
2021-05-12
Accepted
2021-05-12 16:17:05
Documents
14
Period of Report
2021-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tm2116036d1_8k.htm   iXBRL 8-K 25462
2 EXHIBIT 99.1 tm2116036d1_ex99-1.htm EX-99.1 109417
6 GRAPHIC tm2116036d1_ex99-1img001.jpg GRAPHIC 11570
  Complete submission text file 0001104659-21-065132.txt   337354

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20210512.xsd EX-101.SCH 3190
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20210512_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20210512_pre.xml EX-101.PRE 22713
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2116036d1_8k_htm.xml XML 3615
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 21915330
SIC: 2834 Pharmaceutical Preparations